Methylnaltrexone bromide enteric-coated - Norgine

Drug Profile

Methylnaltrexone bromide enteric-coated - Norgine

Alternative Names: Enteric-coated methylnaltrexone bromide; NRL 011

Latest Information Update: 10 Sep 2012

Price : $50

At a glance

  • Originator Norgine
  • Class Morphine derivatives; Quaternary ammonium compounds; Small molecules
  • Mechanism of Action Opioid mu receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Constipation

Most Recent Events

  • 31 Dec 2003 Phase-II clinical trials in prevention of postoperative Opioid-induced constipation in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top